COMMUNIQUÉS West-GlobeNewswire

OpGen Completes Clinical Trials for its Initial FDA 510(k) Submission
05/02/2019
GAITHERSBURG, Md., Feb. 05, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has completed the clinical trials needed to support its 510(k) submission for the detection of antimicrobial [...]
Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
05/02/2019
BERKELEY HEIGHTS, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12
05/02/2019
REHOVOT, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and [...]
Emerald Health Therapeutics Secures Proprietary Extraction Technology and Extraction Capabilities in Agreement with Indena
05/02/2019
Emerald receives certain exclusive rights to established Phytosome ® technology to enhance absorption and bioavailability of cannabinoid products Leading global extraction researcher and manufacturer to provide license [...]
Microbix Provides Quality Assessment Products Update
05/02/2019
New Customers, More Products, and Expanding Capacity TORONTO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on [...]
BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
05/02/2019
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the ZENITH-1 study at the [...]
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary
05/02/2019
Investment will enable Melt to fund the development of its patented, non-opioid sublingual sedation and analgesia drug candidate, MELT-100 SAN DIEGO and BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, [...]
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
05/02/2019
~ Pharmacokinetic data from patients treated in the study show that infusion of pegunigalsidase alfa every 4 weeks results in the presence of continuous active enzyme throughout the entire infusion interval~ ~Continuous [...]
Revive Announces Closing of the First Tranche of Its Non-Brokered Private Placement for Total Gross Proceeds of Over $1 Million
05/02/2019
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics [...]
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
05/02/2019
Patient safety is primary imperative ORLEANS, Ontario, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily [...]
CorVel Announces Revenues and Earnings
05/02/2019
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended December 31, 2018. Revenues for the quarter ended December 31, 2018 were $146 million, an [...]
Coloplast delivers solid start to the year with 8% organic growth
05/02/2019
Coloplast delivered 8% organic growth and EBIT increased by 8% to DKK 1,297m, corresponding to an EBIT margin of 30%, in the first quarter of the 2018/19 financial year. The company maintains its financial guidance for [...]
Press release: Terveystalo dental clinic network expands - Länsi-Vantaan Hammaslääkärit Oy to become a part of Terveystalo
05/02/2019
Terveystalo has signed an agreement to acquire Länsi-Vantaan Hammaslääkärit Oy, a private clinic that offers oral health services in Vantaa. The company's employees will be transferred to Terveystalo as old employees [...]
Announcement no. 1/2019 – Interim Financial Report, Q1 2018/19
05/02/2019
Q1 2018/19 Interim financial report, Q1 2018/19 (01 October 2018 - 31 December 2018) Solid start to the year, guidance for 2018/19 maintained Coloplast delivered 8% organic growth in the first quarter. Reported revenue [...]
Nu-Med Plus, Inc. Produces New, Smaller, and Smarter Inhaled Nitric Oxide Delivery Unit for Clinical Settings
05/02/2019
Nu-Med Plus’s inhaled nitric oxide clinical unit is designed to open new patient markets by providing in-office treatment options for conditions such as high blood pressure, COPD and ARDS SALT LAKE CITY, Feb. 05, 2019 ( [...]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) - UPDATED VERSION
05/02/2019
THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1, 752 28 UPPSALA. [...]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)
05/02/2019
THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1, 752 28 UPPSALA. [...]
Transactions in relation to share buyback program
05/02/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
05/02/2019
UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial [...]

Pages